OR WAIT 15 SECS
Funding from Innovate UK will be used by Medherant to support manufacture of transdermal patches for clinical trials.
Medherant, a developer of innovative transdermal drug delivery treatments for pain and central nervous system diseases, has been awarded a Medicines Manufacturing Grant by Innovate UK, the company announced in an Oct. 3, 2018 press release. The grant will enable the company to buy equipment and move forward with its plans to extend its pilot-scale manufacture of patches formulated with its unique TEPI Patch technology to GMP manufacture for clinical trials.
The patent-protected patch technology enables the development of drug-in-adhesive patch products with better adhesion and more efficient delivery of drugs through the skin over a prolonged period. Medherant's first product, an ibuprofen TEPI Patch, is in Phase I clinical development with initial results expected in Q4 2018. Medherant's business model is to develop products to then out-license to established pharmaceutical companies for commercialization.
Medherant recently installed its own pilot-scale patch manufacturing plant and has successfully produced non-GMP patches of the ibuprofen TEPI Patch. The company has also produced patches for third parties interested in assessing the suitability of the TEPI technology for their drugs. Medherant’s high-throughput permeation assessment process rapidly identifies formulations that meet the target drug release profile, enabling the creation of candidate patch formulations in only two to three months.